Buprenorphine/Naloxone Treatment for Opioid Dependence-Experiment I(2) - 2

Withdrawn before enrolling · Phase 2

Conditions studied: Heroin Dependence, Opioid-Related Disorders

In brief

The purpose of this study is to compare the clinical efficacy of daily vs. 3-day (MWF) buprenorphine/naloxone combination tablet administration and determine whether outcomes are improved when using a 3-day schedule in which all doses are ingested at the clinic vs. one in which take-home doses are given on intervening days.

Key facts

Study ID

NCT00000327

Run by

University of Colorado, Denver

People needed

0

Starts

1997-06-01

Expected to finish

1997-08-01

Last updated by the study team

2017-05-04

Who can join

Age: 18 and older, up to 62. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Individual must be currently dependent and meet FDA criteria for narcotic maintenance treatment. Co-morbid substance abuse or dependence disorders may also be present. Individuals must be healthy despite drug dependency.

You may not qualify if…

• Individuals with evidence of an active Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) Axis I psychiatric disorder (e.g., psychosis, manic-depressive illness, organic psychiatric disorders), significant medical illness (e.g. liver or cardiovascular disease) or pregnant female subjects are excluded from study participation.

Where it is running

• University of Colorado Health Sciences Center — Denver, Colorado, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.